288 related articles for article (PubMed ID: 1380890)
21. Cross talk of tumor necrosis factor-alpha and epidermal growth factor in human microvascular endothelial cells.
Izumi H; Ono M; Ushiro S; Kohno K; Kung HF; Kuwano M
Exp Cell Res; 1994 Oct; 214(2):654-62. PubMed ID: 7523156
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
[TBL] [Abstract][Full Text] [Related]
23. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
Langton-Webster BC; Xuan JA; Brink JR; Salomon DS
Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
[TBL] [Abstract][Full Text] [Related]
24. Modulation of EGF receptor by tumor necrosis factor-alpha in human hepatocellular carcinoma HepG2 cells.
Wang D; Yang EB; Cheng LY
Anticancer Res; 1996; 16(5A):3001-6. PubMed ID: 8917420
[TBL] [Abstract][Full Text] [Related]
25. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
Mathur RS; Mathur SP
Gynecol Oncol; 2005 Apr; 97(1):206-13. PubMed ID: 15790460
[TBL] [Abstract][Full Text] [Related]
27. Expression of functional epidermal growth factor receptors in a human hematopoietic cell line.
Oval J; Hershberg R; Gansbacher B; Gilboa E; Schlessinger J; Taetle R
Cancer Res; 1991 Jan; 51(1):150-6. PubMed ID: 1703031
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
29. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
Mishra S; Mathur R; Hamburger AW
Lymphokine Cytokine Res; 1994 Apr; 13(2):77-83. PubMed ID: 8061118
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells.
Donato NJ; Rotbein J; Rosenblum MG
J Cell Biochem; 1991 May; 46(1):69-77. PubMed ID: 1874802
[TBL] [Abstract][Full Text] [Related]
34. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
36. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
38. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
39. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
Donato NJ; Gallick GE; Steck PA; Rosenblum MG
J Biol Chem; 1989 Dec; 264(34):20474-81. PubMed ID: 2555361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
